4basebio
Emily Young currently serves as the Formulation Team Lead for non-viral gene delivery at 4basebio since February 2022. Previously, Emily was a BBSRC LIDo Programme PhD Student at UCL from February 2018 to February 2022, focusing on targeted gene therapy for rheumatoid arthritis under the supervision of Professor Stephen Hart and Dr. David Gould. Prior experiences include a PhD Research Internship at Singer Instruments and a Rotation Student position at the London School of Hygiene and Tropical Medicine, where research involved genetic manipulation of Trypanosoma brucei. An industrial placement at UCB in 2015-2016 provided hands-on experience with protein binding and hepatocyte clearance assays. Emily holds a degree in Biomedical Science with Employment Experience from The University of Sheffield, completed in 2017.
4basebio
4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.